Accepted Manuscript

Rethinking Reverse Cholesterol Transport and Dysfunctiohjpownall@HoustonMethodist.orgnal High Density Lipoproteins

Baiba K. Gillard, PhD, Corina Rosales, PhD, Bingqing Xu, MD, Antonio M. Gotto, Jr., MD, DPhil, Henry J. Pownall, PhD

PII: S1933-2874(18)30199-5

DOI: 10.1016/j.jacl.2018.04.001

Reference: JACL 1295

To appear in: Journal of Clinical Lipidology

Received Date: 7 February 2018

Revised Date: 26 March 2018

Accepted Date: 3 April 2018

Please cite this article as: Gillard BK, Rosales C, Xu B, Gotto Jr. AM, Pownall HJ, Rethinking Reverse Cholesterol Transport and Dysfunctiohjpownall@HoustonMethodist.orgnal High Density Lipoproteins, *Journal of Clinical Lipidology* (2018), doi: 10.1016/j.jacl.2018.04.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Rethinking Reverse Cholesterol Transport and Dysfunctional High Density Lipoproteins

Baiba K. Gillard, PhD^{a,b*} Corina Rosales, PhD^{a,b*} Bingqing Xu, MD^c Antonio M. Gotto Jr., MD, DPhil^{a,b}

and Henry J. Pownall, PhD^{a,b}

From the ^aCenter for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston TX 77030, ^bWeill Cornell Medicine, 1305 York Avenue, New York, NY, 10065 USA and the ^cDepartment of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.

*Shared first authors.

Running Title: HDL-lipid and apolipoprotein segregation

Subject Codes: Lipids and cholesterol, metabolism, atherosclerosis, cell biology/structural biology. *Word Count: 9,525*.

Funding: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Numbers HL056865 (CR and HJP), the Bass Foundation (AMG, Fort Worth TX) and Houston Methodist Foundation (Houston TX) funding from Charif Souki, Patrick Studdert and the Jerold B. Katz family.

Disclosures: BKG, CR, and HJP have nothing to disclose. AMG is on the Board of Directors with Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, and Esperion Therapeutics, a member of the Data Safety Monitoring Board for Ionis Pharmaceuticals, and received consulting fees from Kowa Pharmaceuticals, Merck and Co, Pfizer, and Vatera Capital. HJP prepared a n initial draft and

Download English Version:

https://daneshyari.com/en/article/8668300

Download Persian Version:

https://daneshyari.com/article/8668300

Daneshyari.com